Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in the United States and in Japan.
The United States patent office have granted Reapplix’s patent protecting the unique triple layered structure of LeucoPatch (patent no US8,980,301B2). In Japan, the patent office have granted Reapplix’s patent on the device used when producing a LeucoPatch, using the unique 3CP™ technology developed by the company (JP patent no. 5676764).
Reapplix already has strong patent protection in key territories including Europe and these new approvals will further underpin the company’s expansion plans for the future.
Commenting on the news, Niels Erik Holm, Chief Operating Officer at Reapplix said :
“Our portfolio of patents protects both the unique features of LeucoPatch and the device and methods used to produce it. All patent applications take a long time to work through the various review processes so it is always very satisfying when the notification of grant comes through.”
Graeme Brookes, Chief Executive Officer, added:
“Intellectual property is a key asset and the grant of these patents, in two of the most important global healthcare markets, marks a further value creation milestone for the company as we continue to build out our commercialisation plans.”